ArticlebioRxiv : the preprint server for biology2024
PURE-seq identifies
Sixuan Pan, Kai-Chun Chang, Inés Fernández-Maestre, Stéphane Van Haver, Matthew G Wereski, Robert L Bowman, Ross L Levine, Adam R Abate
Abstract readPreprint
In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
8 authors.
Sixuan PanDepartment of Bioengineering, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0009-0001-3795-4903 Kai-Chun ChangDepartment of Bioengineering, University of California San Francisco, San Francisco, CA 94143, USA.
Inés Fernández-MaestreHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Stéphane Van HaverMolecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Matthew G WereskiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Robert L BowmanDepartment of Cancer Biology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Ross L LevineHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-7884-1905 Adam R AbateDepartment of Bioengineering, University of California San Francisco, San Francisco, CA 94143, USA.ORCID 0000-0001-9614-4831 Funding
Synergistic role of signaling and epigenetics in leukemic transformationR35CA197594 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Ross L Levine · 2017 to 2026
$11.4MMulti-omic dissection of the transcriptional, epigenetic, and proteomic signatures of cells infected with latent HIVR01AI149699 · NIAID · BRIGHAM AND WOMEN'S HOSPITAL · PI ABATE, ADAM R., QUINTANA, FRANCISCO J. · 2020 to 2024
$3.8MInflammatory Signaling in DNMT3A-Mutated Human Hematopoietic Stem CellsU01AG077925 · NIA · JACKSON LABORATORY · PI LEVINE, ROSS L, TROWBRIDGE, JENNIFER JEAN · 2021 to 2025
$2.9MIdentification of Regulatory Mechanisms Operating in Rare Pathogenic Astrocyte Subsets in Multiple Sclerosis with a Novel Genomic TechnologyR01NS130876 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Adam R. Abate, CARLO L CONDELLO · 2023 to 2026
$2.3MInterrogating oncogene-dependency and mutation order in FLT3 mutant AMLK99CA248460 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI BOWMAN, ROBERT LYLE · 2020 to 2021
$297kuNDERSTANDING AND TARGETING SENESCENCE IN CLONAL HEMATOPOIESISK00CA284253 · NCI · COLD SPRING HARBOR LABORATORY · PI FERNANDEZ MAESTRE, INES · 2025 to 2025
$101kIdentifying Inflammatory Mediators of Clonal HematopoiesisF99CA284253 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI FERNANDEZ MAESTRE, INES · 2023 to 2024
$75kNCI NIH HHS F99 CA284253NCI NIH HHS K00 CA284253NCI NIH HHS K99 CA248460NCI NIH HHS R35 CA197594NIAID NIH HHS R01 AI149699NIA NIH HHS U01 AG077925NINDS NIH HHS R01 NS130876
6 · The paper itselfAbstract
Single-cell transcriptomics is valuable for uncovering individual cell properties, particularly in highly heterogeneous systems. However, this technique often results in the analysis of many well-characterized cells, increasing costs and diluting rare cell populations. To address this, we developed PURE-seq (PIP-seq for Rare-cell Enrichment and Sequencing) for scalable sequencing of rare cells. PURE-seq allows direct cell loading from FACS into PIP-seq reactions, minimizing handling and reducing cell loss. PURE-seq reliably captures rare cells, with 60 minutes of sorting capturing tens of cells at a rarity of 1 in 1,000,000. Using PURE-seq, we investigated murine long-term hematopoietic stem cells and their transcriptomes in the context of hematopoietic aging, identifying
Identifiers
PMID39185152
PMCPMC11343112
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390